Key facts
- This page summarizes Fosun Pharma USA Inc.'s Form 3 filing for NATURES SUNSHINE PRODUCTS INC (NATR).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 09 Jun 2025, 16:32.
Fosun Pharma USA Inc. - 05 Jun 2025 Form 3 Insider Report for NATURES SUNSHINE PRODUCTS INC (NATR)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- NATR
- Reported as of
- 05 Jun 2025
- Net transaction value
- $0
- Reporting owner signature
- Fosun Pharma USA Inc. By: /s/ Yuqing Wang, Chief Financial Officer
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Fosun Pharma USA Inc. filed Form 3 for NATURES SUNSHINE PRODUCTS INC (NATR) on 09 Jun 2025.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0002071437
Primary reporting owner
Fosun Pharma USA Inc.
- Relationship
- 10%+ Owner
- Address
- 104 CARNEGIE CENTER DRIVE, SUITE 204, PRINCETON
- Signature
- Fosun Pharma USA Inc. By: /s/ Yuqing Wang, Chief Financial Officer
- Signature date
- 09 Jun 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NATR
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 2,854,607
- Date
- 05 Jun 2025
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. transferred these shares to its wholly-owned subsidiary, Fosun Pharma USA Inc. Following the transfer, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. and Fosun Pharma USA Inc. intend to jointly file Section 16 reports with respect to these shares.